Group 1 - The core announcement is that Yantai Dongcheng Pharmaceutical Group Co., Ltd.'s subsidiary, Yantai Lanacheng Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of the drug 177Lu-LNC1009 injection, which targets advanced malignant solid tumors [1][2] - The drug 177Lu-LNC1009 is a dual-target radioactive therapy aimed at FAP-positive and integrin αvβ3-positive patients, showing potential for improved tumor targeting and treatment efficacy [2][3] - The total research and development investment for 177Lu-LNC1009 has reached approximately 13.579 million yuan [2] Group 2 - The company announced that its full subsidiary, Nanjing Jiangyuan Andico Positron Research and Development Co., Ltd., has had its product, Technetium-99m (99mTc) Tetrofosmin injection, included in the National Medical Insurance Directory for 2025, which is expected to enhance market accessibility and promote sales [4] - The inclusion in the medical insurance directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's financial performance in the short term [4]

2025 年 6 月 19 日，浙江大学 林爱福 、 周天华 及 袁瑛 等团队 在 Cell 子刊 Molecular Cell 发表题为 ： Hepatic micropeptide modulates mitochondrial RNA processing machinery in hepatocellular carcinoma 的封面论文 【2】 。 排版丨水成文 人类基因组的复杂性令人叹为观止，但仅约1%的基因编码约两万种蛋白质，而其中被深入研究的仅有几千 种，被认为具有作为药物或检测靶点的更是屈指可数。陆续有研究表明，人类基因组中曾被认为不具备编 码功能的非编码区，同样蕴藏着编码蛋白质的潜力。这些如同"暗物质"般神秘的未被充分研究蛋白质，可 能蕴藏着治疗包括癌症在内多种疾病的关键钥匙，其系统鉴定将为生物学与医学研究带来新思路。 近期，浙江大学 林爱福 与 周天华 团队在人类胃癌等组织样本中鉴定出近万个尚未被充分解析的新型 微肽 ，并借助人工智能 （AI） 技术对其功能进行了系统注释，为肿瘤等恶性疾病的预防和干预提供了新的靶点 和思路。 相 关 论 文 以 ： Comprehensive Disc ...